Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Xanax · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Xanax XR tablets 3 mg (sourced from Caugus) | ACTIVE_COMPARATOR | Xanax XR tablets 3 mg (sourced from Caugus), 1 x 3 mg (REFERENCE) |
| Xanax XR tablets 3 mg (sourced from Barceloneta), | EXPERIMENTAL | Xanax XR tablets 3 mg (sourced from Barceloneta), 1 x 3 mg (TEST) |
| Name | Type | Description |
|---|---|---|
| Xanax XR tablets 3 mg (sourced from Caugus) | DRUG | Tablets, 3 mg, single dose |
| Xanax XR tablets 3 mg (sourced from Barceloneta) | DRUG | Tablets, 3 mg, single dose |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 20 and 55 years, inclusive. * An informed consent document signed and dated by the subject. Exclusion Criteria: * Evidence or history of clinically significant abnormality. * A positive urine drug screen. * Subjects who...
Xanax is an investigational small molecule being studied in healthy subjects. A completed Phase 1 bioequivalence study evaluated Xanax extended release tablets from two different manufacturing sites. The study enrolled 16 participants in Singapore, with a minimum age of 20 years.
Xanax is being developed by Pfizer, Inc., which trades under the ticker PFE. The company conducted a Phase 1 clinical trial of the drug in healthy subjects.
Xanax is in Phase 1 clinical development. One Phase 1 study has been completed, and there are no active trials currently listed. The drug remains investigational and is not approved.
Xanax has one completed clinical trial, NCT01330472, titled 'An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites.' This Phase 1 study enrolled 16 healthy subjects in Singapore and was active-controlled.
Xanax is the brand name for alprazolam, a small molecule. The clinical trial NCT01330472 studied Xanax extended release tablets, comparing tablets from two manufacturing sites for bioequivalence.